Group 1 - The core point of the article is the establishment of a new health technology company, Jianxiaoxiang Health Technology (Shenzhen) Co., Ltd., which is fully owned by Langkun Technology [1] - The registered capital of the new company is 10 million yuan, indicating a significant investment in the health technology sector [1] - The business scope of the new company includes human gene diagnosis and treatment technology development, AI industry application system integration services, and AI theory and algorithm software development [1]

Core Viewpoint - The company has established a wholly-owned subsidiary in the Qianhai Free Trade Zone, Shenzhen, with a registered capital of up to 22 million yuan, focusing on human genetic diagnosis and treatment technology development [1] Group 1 - The board meeting was held in January 2026 to approve the establishment of the subsidiary [1] - The newly formed subsidiary is named Xinlitai Life Sciences (Shenzhen) Co., Ltd. and has completed its business registration [1] - The legal representative of the subsidiary is Xu Wenjie [1]